Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Takeda/Ovid Broaden Pioneering CH24H Inhibitor To Rare Epilepsies

Jul 20 2018

• By Ian Haydock

nerve cells, concept for neurodegenerative and neurological disease — TAKEDA/OVID PROGRESS NOVEL THERAPY FOR RARE EPILEPSIES • Source: Shutterstock

Related Content

Takeda Targets Severe Epilepsies In Ovid Alliance

Jan 19 2017

Related Companies

Takeda Pharmaceutical Co. Ltd.

Ovid Therapeutics, Inc.

GW Pharmaceuticals plc

H. Lundbeck A/S

Daiichi Sankyo Co., Ltd.

Zogenix, Inc.

Eisai Co., Ltd.

GSK plc

Additional Topics

Clinical Trials Research & Development Neurology BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window